Drug Profile
Research programme: glaucoma therapeutics - Icagen
Latest Information Update: 24 Jul 2007
Price :
$50
*
At a glance
- Originator Icagen
- Class
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 24 Jul 2007 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
- 21 Aug 2006 Icagen may selectively consider partnering opportunities for this programme(http://www.icagen.com)
- 21 Aug 2006 Preclinical trials in Glaucoma in USA (Ophthalmic)